BIOMAT Database Logo BIOMAT Database Logo

HIV-1 P24 antigenaemia does not predict time of survival in AIDS patients. 1990

J W Mulder, and P Krijnen, and J Goudsmit, and J K Schattenkerk, and P Reiss, and J M Lange
Department of Internal Medicine, University of Amsterdam.

The time of survival in 176 AIDS patients was investigated in relation to the presence or absence of HIV-1 p24 antigenaemia at the moment of diagnosis. The median time of survival in p24 antigen positive patients was 12 months, in p24 antigen negative patients it was 13 months; no difference in survival curves was found. Also no difference was found in survival between patients with high and low p24 antigen levels. The median time of survival in patients for whom a diagnosis of AIDS was made in the period before the introduction of zidovudine treatment was 10 months; in patients diagnosed in the period thereafter it was 18 months (p less than 0.005). However, when each period was analysed separately, no difference in survival between p24 antigen positive and negative patients was found. Separate analysis of patients with a diagnosis of Kaposi's sarcoma alone showed similar results. HIV-1 p24 antigenaemia at the moment of diagnosis of AIDS (both in the period before and in the period after the introduction of zidovudine) is not a predictor for time of survival.

UI MeSH Term Description Entries
D008297 Male Males
D011237 Predictive Value of Tests In screening and diagnostic tests, the probability that a person with a positive test is a true positive (i.e., has the disease), is referred to as the predictive value of a positive test; whereas, the predictive value of a negative test is the probability that the person with a negative test does not have the disease. Predictive value is related to the sensitivity and specificity of the test. Negative Predictive Value,Positive Predictive Value,Predictive Value Of Test,Predictive Values Of Tests,Negative Predictive Values,Positive Predictive Values,Predictive Value, Negative,Predictive Value, Positive
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000163 Acquired Immunodeficiency Syndrome An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993. AIDS,Immunodeficiency Syndrome, Acquired,Immunologic Deficiency Syndrome, Acquired,Acquired Immune Deficiency Syndrome,Acquired Immuno-Deficiency Syndrome,Acquired Immuno Deficiency Syndrome,Acquired Immuno-Deficiency Syndromes,Acquired Immunodeficiency Syndromes,Immuno-Deficiency Syndrome, Acquired,Immuno-Deficiency Syndromes, Acquired,Immunodeficiency Syndromes, Acquired,Syndrome, Acquired Immuno-Deficiency,Syndrome, Acquired Immunodeficiency,Syndromes, Acquired Immuno-Deficiency,Syndromes, Acquired Immunodeficiency
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D012514 Sarcoma, Kaposi A multicentric, malignant neoplastic vascular proliferation characterized by the development of bluish-red cutaneous nodules, usually on the lower extremities, most often on the toes or feet, and slowly increasing in size and number and spreading to more proximal areas. The tumors have endothelium-lined channels and vascular spaces admixed with variably sized aggregates of spindle-shaped cells, and often remain confined to the skin and subcutaneous tissue, but widespread visceral involvement may occur. Kaposi's sarcoma occurs spontaneously in Jewish and Italian males in Europe and the United States. An aggressive variant in young children is endemic in some areas of Africa. A third form occurs in about 0.04% of kidney transplant patients. There is also a high incidence in AIDS patients. (From Dorland, 27th ed & Holland et al., Cancer Medicine, 3d ed, pp2105-7) HHV-8 is the suspected cause. Kaposi Sarcoma,Kaposi's Sarcoma,Multiple Idiopathic Pigmented Hemangiosarcoma,Kaposis Sarcoma,Sarcoma, Kaposi's
D014758 Viral Core Proteins Proteins found mainly in icosahedral DNA and RNA viruses. They consist of proteins directly associated with the nucleic acid inside the NUCLEOCAPSID. Core Proteins, Viral,Major Core Protein,Major Core Proteins, Viral,Adenovirus Core Protein VII,Core Protein V,Core Protein lambda 2,Influenza Virus Core Proteins,Major Core Protein lambda 1,Major Core Protein lambda-1,Major Core Protein sigma 2,Major Core Protein sigma-2,OVP 19,Oncornaviral Protein P19,P30 Core Proteins,Viral Protein P19,Virus Core Proteins,Core Protein, Major,Core Proteins, P30,Core Proteins, Virus,Protein P19, Oncornaviral,Protein P19, Viral,Protein, Major Core,Proteins, P30 Core,Proteins, Viral Core,Proteins, Virus Core
D015488 HIV Antigens Antigens associated with specific proteins of the human adult T-cell immunodeficiency virus (HIV); also called HTLV-III-associated and lymphadenopathy-associated virus (LAV) antigens. AIDS Antigens,HIV-Associated Antigens,HTLV-III Antigens,HTLV-III-LAV Antigens,LAV Antigens,Lymphadenopathy-Associated Antigens,T-Lymphotropic Virus Type III Antigens, Human,HIV Associated Antigens,HTLV III Antigens,HTLV III LAV Antigens,Lymphadenopathy Associated Antigens,T Lymphotropic Virus Type III Antigens, Human,Antigens, AIDS,Antigens, HIV,Antigens, HIV Associated,Antigens, HIV-Associated,Antigens, HTLV III,Antigens, HTLV-III,Antigens, HTLV-III-LAV,Antigens, LAV,Antigens, Lymphadenopathy Associated,Antigens, Lymphadenopathy-Associated,Associated Antigens, HIV,Associated Antigens, Lymphadenopathy,III Antigens, HTLV
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human

Related Publications

J W Mulder, and P Krijnen, and J Goudsmit, and J K Schattenkerk, and P Reiss, and J M Lange
Abundance of early functional HIV-specific CD8+ T cells does not predict AIDS-free survival time.
July 2008, PloS one,
J W Mulder, and P Krijnen, and J Goudsmit, and J K Schattenkerk, and P Reiss, and J M Lange
CD4+:neopterin ratio correlates with p24 antigenaemia in HIV infected patients.
February 1990, Journal of clinical & laboratory immunology,
J W Mulder, and P Krijnen, and J Goudsmit, and J K Schattenkerk, and P Reiss, and J M Lange
p24 antigenaemia, CD4 lymphocyte counts and the development of AIDS.
October 1991, AIDS (London, England),
J W Mulder, and P Krijnen, and J Goudsmit, and J K Schattenkerk, and P Reiss, and J M Lange
Quantitative p24 antigenaemia for monitoring response to antiretroviral therapy in HIV-1 group O-infected patients.
January 1998, Antiviral therapy,
J W Mulder, and P Krijnen, and J Goudsmit, and J K Schattenkerk, and P Reiss, and J M Lange
The effect of treatment with zidovudine with or without acyclovir on HIV p24 antigenaemia in patients with AIDS or AIDS-related complex.
August 1992, AIDS (London, England),
J W Mulder, and P Krijnen, and J Goudsmit, and J K Schattenkerk, and P Reiss, and J M Lange
p24 antigenaemia in HIV-1 infected Brazilians correlates with other markers of disease progression.
September 1994, The Journal of infection,
J W Mulder, and P Krijnen, and J Goudsmit, and J K Schattenkerk, and P Reiss, and J M Lange
Free and decomplexed human immunodeficiency virus p24 antigenaemia in black patients with AIDS and AIDS-related disorders.
January 1993, The European journal of medicine,
J W Mulder, and P Krijnen, and J Goudsmit, and J K Schattenkerk, and P Reiss, and J M Lange
Decline of anti-p24 antibody precedes antigenaemia as correlate of prognosis in HIV-1 infection.
December 1987, AIDS (London, England),
J W Mulder, and P Krijnen, and J Goudsmit, and J K Schattenkerk, and P Reiss, and J M Lange
Early confirmation of HIV p24 antigenaemia in infants born of HIV-positive mothers.
May 1993, The Journal of infection,
J W Mulder, and P Krijnen, and J Goudsmit, and J K Schattenkerk, and P Reiss, and J M Lange
Donor HIV-1 p24 antigenaemia and course of infection in recipients Transfusion Safety Study Group.
June 1990, Lancet (London, England),
Copied contents to your clipboard!